Scientists claim that the COVID study of ivermectin was flawed.
Scientists have challenged a study on ivermectin that claimed it had a favorable outcome when administered to COVID patients.
A double-blind, randomized experiment was conducted in Israel in May 2021 to compare non-hospitalized patients who were given ivermectin three days ago with those who were given a placebo. There were 47 patients in the ivermectin and 42 in the placebo groups.
According to a preprint on the medRxiv preprint repository, it was found that ivermectin-treated patients had lower viral loads and viable cultures than a placebo group. It has been referenced by many news outlets.
Gideon MeyerowitzKatz, a scientist and chronic illness researcher, attacked the findings in a series tweets posted Tuesday.
Ivermectin supporters often cite this study, which has been widely publicized. It is an excellent teaching tool because it shows how easy it is to be skeptical about research findings.
He claims that the final study is different from the one the study authors promised during pre-registration. You can pre-register for the study here.
Meyerowitz-Katz says the discrepancy is caused by those who were excluded from the study on the basis of their CT value. This is a measure how many viruses someone has in their system.
According to the study, COVID patients who had a CT value greater than 35 in the first two tests were not included in the initial exclusion criteria. Meyerowitz-Kats said, “It appears that the authors have added an additional exclusion criteria that is applied following randomization and treatment.” He continued, “If you add those folks back in to the study, it loses all significance.”